Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report

Small-cell lung cancer (SCLC) is characterized by rapid proliferation, high growth fraction and early locoregional and distant metastases. SCLC has been found to be significantly sensitive to platinum–etoposide chemotherapy, but most patients relapse within 6 months of completing initial treatment a...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2022-09, Vol.14 (13), p.1007-1013
Main Authors: Wu, Guixian, Huang, Jing, Lin, Ling, Yan, Shuangquan, Pan, Weijia, Chen, Qian, Wu, Xiaomai, Lv, Dongqing
Format: Article
Language:English
Subjects:
anlotinib
antiangiogenic drug
immunotherapy resistance
maintenance treatment
PD-L1 antibody
small-cell lung cancer (SCLC)
toripalimab
tumor microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small-cell lung cancer (SCLC) is characterized by rapid proliferation, high growth fraction and early locoregional and distant metastases. SCLC has been found to be significantly sensitive to platinum–etoposide chemotherapy, but most patients relapse within 6 months of completing initial treatment and median overall survival is about 10 months. Despite the current immunotherapy-treatment approach, median survival time and progression-free survival remain short. This case shows the potential efficacy of maintenance therapy with toripalimab and anlotinib after first-line platinum–etoposide chemotherapy in a patient with extensive-stage SCLC. The combination treatment prolonged the progression-free survival to approximately 13 months and overall survival to 25 months; this is well above the existing standard, and this patient did not experience any major adverse effects during the course of therapy.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2021-0147